Clinical artificial intelligence (AI) solutions provider Aidoc has expanded its partnership with Integral Diagnostics (IDX), a provider of AI-driven medical imaging services, in Australia and New Zealand.
The expanded collaboration, which started four years ago, enhances AI-driven medical imaging services, leveraging Aidoc’s aiOS platform.
aiOS is designed to alert radiologists and care teams to suspected and unsuspected critical findings in medical images. It also prioritises abnormal findings and improves patient care quality and timeliness of patients in the region.
Aidoc’s AI technology has supported IDX to advance AI-driven medical imaging in Australia and New Zealand.
The aiOS platform automatically flags critical pathologies, such as brain aneurysms, pulmonary embolisms, strokes, and brain bleeds.
Since 2019, Israel-based Aidoc has processed over 600,000 cases across IDX’s network and partner facilities.
Aidoc announced few other major advancements are coming. Starting in July 2025, the Australian Government will fund the National Lung Cancer Screening Programme (NLCSP) to enhance early lung cancer detection.
IDX is currently testing a new algorithm within Aidoc’s aiOS platform, designed to notify radiologists about lung nodules and measure them accurately. This will enable earlier and more effective interventions for lung cancer.
Integral Diagnostics CEO and managing director Ian Kadish said: “Aidoc’s AI has significantly improved patient care and service.
“We’re keen to test and use their Chest CT AI algorithms to automate our reviews in the National Lung Cancer Screening Programme to enable us to detect disease earlier, more accurately and more efficiently.”
Widely adopted in the US and Europe, Aidoc’s aiOS platform analyses over three million patients monthly and is supported by over 150 published studies.
The technology is intended to reduce costs, improve patient outcomes, and increase efficiency.
Furthermore, the partnership between Aidoc and IDX is expected to advance the radiology sector. Both firms will focus on early detection, better patient outcomes, and enhanced healthcare efficiency.
Aidoc business development senior director Rotem Geslevich said: “Our partnership with Integral Diagnostics underscores our commitment to driving better health outcomes.
“As the Lung Cancer Screening initiative approaches, we are excited to play a pivotal role in saving lives.”
Last month, the clinical AI solutions provider introduced seven new AI solutions to the European healthcare market. This also enabled the aiOS platform to now offer 26 AI solutions.
